Conjugal multiple system atrophy: Computing chance or investigating real patients?

08:00 EDT 14th March 2020 | BioPortfolio

Summary of "Conjugal multiple system atrophy: Computing chance or investigating real patients?"

No Summary Available


Journal Details

This article was published in the following journal.

Name: Parkinsonism & related disorders
ISSN: 1873-5126


DeepDyve research library

PubMed Articles [19411 Associated PubMed Articles listed on BioPortfolio]

Conjugal multiple system atrophy: Be wary of implicating transmissibility.

Conjugal cerebellar type of multiple system atrophy: Person-to-person transmission?

Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy.

Radiological biomarkers have been reported for multiple system atrophy and progressive supranuclear palsy, but serum/plasma biomarkers for each disorder have not been established. In this context, we ...

Differences in cerebellar perfusion between Parkinson's disease and multiple system atrophy.

Objective biomarkers are required for differential diagnosis of Parkinson's disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP).

Longitudinal Change of DAT SPECT in Parkinson's Disease and Multiple System Atrophy.

Both Parkinson's disease (PD) and multiple system atrophy (MSA) are neurodegenerative disorder affecting striatonigral system. Although various lines of evidence demonstrate that dopaminergic neuron d...

Clinical Trials [13525 Associated Clinical Trials listed on BioPortfolio]

Safety and Tolerability of CS10BR05 Inj. in Subjects With Multiple System Atrophy

The purpose of conducting phase 1 trial is to evaluate the safety and tolerability of autologous bone marrow-derived mesenchymal stem cells(CS10BR05) in subjects with Multiple System Atrop...

Multiple System Atrophy Multidisciplinary Clinic

This is a prospective cohort study to examine the disease burden of multiple system atrophy and the impact of multidisciplinary care on quality of life and caregiver burden. Data will be c...

Lituximab for Multiple System Atrphy

Neuroprotective or anti-inflammatory strategies are invaluable in multiple system atrophy (MSA) due to its rapid progression with fatal prognosis. We evaluated the efficacy of rituximab in...

Safinamide for Multiple System Atrophy (MSA)

The study is a placebo controlled study, with two parallel arms, in which participants will be randomly assigned in a 2:1 ratio to receive either active (200 mg safinamide) or placebo in a...

Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial

A purpose of the present study is to investigate the capability of serum uric acid elevation, safety, and tolerability of inosine 5'-monophosphate in patients with multiple system atrophy ...

Medical and Biotech [MESH] Definitions

Storing and processing data on multiple servers that can be accessed through the Internet.

A group of inherited and sporadic disorders which share progressive ataxia in combination with atrophy of the CEREBELLUM; PONS; and inferior olivary nuclei. Additional clinical features may include MUSCLE RIGIDITY; NYSTAGMUS, PATHOLOGIC; RETINAL DEGENERATION; MUSCLE SPASTICITY; DEMENTIA; URINARY INCONTINENCE; and OPHTHALMOPLEGIA. The familial form has an earlier onset (second decade) and may feature spinal cord atrophy. The sporadic form tends to present in the fifth or sixth decade, and is considered a clinical subtype of MULTIPLE SYSTEM ATROPHY. (From Adams et al., Principles of Neurology, 6th ed, p1085)

The study of chance processes or the relative frequency characterizing a chance process.

A progressive neurodegenerative condition of the central and autonomic nervous systems characterized by atrophy of the preganglionic lateral horn neurons of the thoracic spinal cord. This disease is generally considered a clinical variant of MULTIPLE SYSTEM ATROPHY. Affected individuals present in the fifth or sixth decade with ORTHOSTASIS and bladder dysfunction; and later develop FECAL INCONTINENCE; anhidrosis; ATAXIA; IMPOTENCE; and alterations of tone suggestive of basal ganglia dysfunction. (From Adams et al., Principles of Neurology, 6th ed, p536)

A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92)

Quick Search

DeepDyve research library

Searches Linking to this Article